Consultation psychiatry in COVID-19 patients: Lopinavir/ritonavir interactions with main psychiatric drugs.
作者信息
Marcatili Matteo, Stefana Alberto, Colmegna Fabrizia, di Giacomo Ester, D'Amico Emiliano, Capuzzi Enrico, Dakanalis Antonios, Clerici Massimo
机构信息
Psychiatric Department, San Gerardo Hospital, ASST Monza, Monza, Italy.
Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
出版信息
Psychiatry Clin Neurosci. 2021 Apr;75(4):145-146. doi: 10.1111/pcn.13205. Epub 2021 Feb 25.
Abstract
摘要
相似文献
1
Consultation psychiatry in COVID-19 patients: Lopinavir/ritonavir interactions with main psychiatric drugs.
Psychiatry Clin Neurosci. 2021 Apr;75(4):145-146. doi: 10.1111/pcn.13205. Epub 2021 Feb 25.
2
Comparative Antiviral Efficacy of Viral Protease Inhibitors against the Novel SARS-CoV-2 In Vitro.
Virol Sin. 2020 Dec;35(6):776-784. doi: 10.1007/s12250-020-00288-1. Epub 2020 Sep 10.
3
Interactions of recommended COVID-19 drugs with commonly used psychotropics.
Asian J Psychiatr. 2020 Aug;52:102173. doi: 10.1016/j.ajp.2020.102173. Epub 2020 May 21.
4
The effect of potential therapeutic agents on QT interval in patients with COVID-19 Infection: The importance of close monitoring and correction of electrolytes.
Med Hypotheses. 2020 Oct;143:109847. doi: 10.1016/j.mehy.2020.109847. Epub 2020 May 16.
5
QTc prolongation during antiviral therapy in two COVID-19 patients.
J Clin Pharm Ther. 2020 Oct;45(5):1190-1193. doi: 10.1111/jcpt.13183. Epub 2020 Jul 21.
6
Effect of hydroxychloroquine, azithromycin and lopinavir/ritonavir on the QT corrected interval in patients with COVID-19.
J Electrocardiol. 2021 Jan-Feb;64:30-35. doi: 10.1016/j.jelectrocard.2020.11.012. Epub 2020 Nov 28.
7
Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Drugs. 2003;63(8):769-802. doi: 10.2165/00003495-200363080-00004.
8
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
Eur J Pharmacol. 2021 Feb 15;893:173813. doi: 10.1016/j.ejphar.2020.173813. Epub 2020 Dec 18.
9
Smartphone electrocardiogram for QT interval monitoring in Coronavirus Disease 2019 (COVID-19) patients treated with Hydroxychloroquine.
Med J Malaysia. 2021 Mar;76(2):125-130.
10
Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
Clin Exp Pharmacol Physiol. 2021 Feb;48(2):203-210. doi: 10.1111/1440-1681.13425. Epub 2020 Nov 7.
引用本文的文献
1
Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.
Eur J Drug Metab Pharmacokinet. 2023 May;48(3):221-240. doi: 10.1007/s13318-023-00826-8. Epub 2023 Apr 24.
2
Revealing the toxicity of lopinavir- and ritonavir-containing water and wastewater treated by photo-induced processes to Danio rerio and Allivibrio fischeri.
Sci Total Environ. 2022 Jun 10;824:153967. doi: 10.1016/j.scitotenv.2022.153967. Epub 2022 Feb 17.
本文引用的文献
1
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
2
Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.
Br J Clin Pharmacol. 2015 Sep;80(3):342-50. doi: 10.1111/bcp.12668. Epub 2015 Jun 1.
3
Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics.
Ann Pharmacother. 2013 Jan;47(1):75-89. doi: 10.1345/aph.1R343. Epub 2013 Jan 22.
4
Carbamazepine toxicity induced by lopinavir/ritonavir and nelfinavir.
Ann Pharmacother. 2006 Jun;40(6):1190-5. doi: 10.1345/aph.1G630. Epub 2006 May 23.
5
Blockade of HERG channels by HIV protease inhibitors.
Lancet. 2005;365(9460):682-6. doi: 10.1016/S0140-6736(05)17950-1.
6
Drugs as P-glycoprotein substrates, inhibitors, and inducers.
Drug Metab Rev. 2002 Feb-May;34(1-2):47-54. doi: 10.1081/dmr-120001389.
7
Indinavir concentrations and St John's wort.
Lancet. 2000 Feb 12;355(9203):547-8. doi: 10.1016/S0140-6736(99)05712-8.
8
Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.
Br J Clin Pharmacol. 1997 Aug;44(2):190-4. doi: 10.1046/j.1365-2125.1997.00644.x.
9
HIV-1 protease inhibitors. A review for clinicians.
JAMA. 1997 Jan 8;277(2):145-53.
Zotero 插件